Our data suggest that the addition of copanlisib to HER2-targeted therapy should be considered for clinical trial evaluation in patients with HER2-positive GC, particularly in those patients with PI3K pathway activated tumours. The gene discussed is ERBB2; the disease is gastric cancer.